Agents that specifically bind PD-L1 are disclosed. The PD-L1-binding agents may include polypeptides, antibodies, bispecific agents, homodimeric molecules, and/or heterodimeric molecules. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.